Already a member?
Login
Become a member
Register
About
About PCSK9 Forum
Editorial Board
Mission Statement
Home
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
Expert Meetings
News
News
Meeting Reports
Commentary
Hot topics
From the Editors
Expert views
Slides
Slide Resource Programme
Slides by Editorial Board
Trials
Videos
Resources
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– Home
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
Expert Meetings
News
– News
– Meeting Reports
– Hot topics
– From the Editors
– Expert views
Slides
– Slide Resource Programme
– Slides by Editorial Board
Trials
Videos
Resources
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
PCSK9 inhibition with a novel fusion protein
Oral PCSK9 inhibition: Clinical update
VICTORION-INITIATE supports early inclisiran treatment in ASCVD
LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD
US patients missing out on bempedoic acid
Evolocumab benefits in patients with autoimmune and inflammatory diseases
Latest News Updates
Slide resources from the PCSK9 Forum Expert Editorial Board: Why you need to take a second look
Posted on
24 June 2019
|
Related content